Patient-specific Boolean models of signalling networks guide personalised treatments

• Verfasst von: Montagud, Arnau [VerfasserIn]
• Verfasst von: Béal, Jonas [VerfasserIn]
• Verfasst von: Tobalina, Luis [VerfasserIn]
• Verfasst von: Traynard, Pauline [VerfasserIn]
• Verfasst von: Subramanian, Vigneshwari [VerfasserIn]
• Verfasst von: Szalai, Bence [VerfasserIn]
• Verfasst von: Alföldi, Róbert [VerfasserIn]
• Verfasst von: Puskás, László [VerfasserIn]
• Verfasst von: Valencia, Alfonso [VerfasserIn]
• Verfasst von: Barillot, Emmanuel [VerfasserIn]
• Verfasst von: Sáez Rodríguez, Julio [VerfasserIn]
• Verfasst von: Calzone, Laurence [VerfasserIn]
• Titel: Patient-specific Boolean models of signalling networks guide personalised treatments
• Verf.angabe: Arnau Montagud, Jonas Béal, Luis Tobalina, Pauline Traynard, Vigneshwari Subramanian, Bence Szalai, Róbert Alföldi, László Puskás, Alfonso Valencia, Emmanuel Barillot, Julio Saez-Rodriguez, Laurence Calzone
• E-Jahr: 2022
• Jahr: Feb 15, 2022
• Umfang: 81 S.
• Fussnoten: Gesehen am 27.06.2022
• Titel Quelle: Enthalten in: eLife
• Ort Quelle: Cambridge : eLife Sciences Publications, 2012
• Jahr Quelle: 2022
• Band/Heft Quelle: 11(2022), Artikel-ID e72626, Seite 1-81
• ISSN Quelle: 2050-084X
• DOI: doi:10.7554/eLife.72626
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: drug combinations
• Sach-SW: logical modelling
• Sach-SW: personalised drug
• Sach-SW: personalised medicine
• Sach-SW: prostate cancer
• Sach-SW: simulations
• K10plus-PPN: 1807860841

Abstract

Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. A total of 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology.